SciClone Pharmaceuticals to Report Financial Results for the Third Quarter 2012 and 2012 Outlook on November 9th FOSTER CITY, CA -- (Marketwire) -- 11/08/12 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report third quarter 2012 financial results and 2012 outlook on Friday, November 9, 2012. SciClone will host a conference call and webcast to provide a business and product update at 8:30 am ET that day. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Gary Titus, Senior Vice President and CFO. LIVE CALL: 877-261-8992 (U.S./Canada) 847-619-6548 (International) Passcode: 33695874 REPLAY: 888-843-7419 (U.S./Canada) 630-652-3042 (International) Passcode: 33695874 (Replay available from Friday, November 9, 2012, at 11:00 am ET until 11:59 pm ET on Wednesday, November 14, 2012) The conference call will contain forward-looking statements. Interested parties who wish to listen to the webcast should visit the Investor Relations section of SciClone's website at www.sciclone.com. The information provided on the teleconference is accurate only at the time of the conference call, and SciClone will take no responsibility for providing updated information except as required by law. About SciClone SciClone Pharmaceuticals is a revenue-generating, profitable, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. SciClone's ZADAXIN(R) (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), as a vaccine adjuvant, and certain cancers according to the local regulatory approvals. Besides ZADAXIN, SciClone markets about 15 mostly partnered products in China, including Depakine(R), the most widely prescribed broad-spectrum anti-convulsant in China; Tritace(R), an ACE inhibitor for the treatment of hypertension; Stilnox(R), a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien(R) in the US); and Aggrastat(R), a recently-launched interventional cardiology product. SciClone is also pursuing the registration of sever al other therapeutic products in China. SciClone is headquartered in Foster City, California. For additional information, please visit www.sciclone.com. Ambien, Depakine, Stilnox and Tritace are registered trademarks of Sanofi and/or its affiliates. Aggrastat is a registered trademark of Medicure International Inc. in the United States, and Iroko Cardio LLC in numerous other countries. SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals design, the SciClone logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc. in the United States and numerous other countries. Corporate Contacts: Gary Titus Chief Financial Officer 650.358.3456 email@example.com Jane Green Investors/Media 650.358.1447 firstname.lastname@example.org
SciClone Pharmaceuticals to Report Financial Results for the
Press spacebar to pause and continue. Press esc to stop.